Skip to main content

Smith & Nephew Request Dismissal of 55 Hip Implant Lawsuits

Smith & Nephew Request Dismissal of 55 Hip Implant Lawsuits

Smith & Nephew Request Dismissal of 55 Hip Implant Lawsuits

Introduction

Birmingham Hip Resurfacing (BHR) System manufacturer Smith & Nephew PLC appealed to a Maryland federal court to dismiss 55 claims from the federal MDL stating the statute of limitation has expired on those cases.

Each patient involved in the claim was meant to file a case within a stipulated time from the date of their surgery. The manufacturer insisted that the patients were not eligible to fight the case considering they had missed the time period allotted to file the lawsuit against the company.

Several Birmingham Hip Replacement lawsuits are federally-filed against Smith & Nephew, 140 of which have been combined into a major federal litigation. Hip replacement lawsuits continue to be filed under a related hip litigation involving Stryker Hip Replacement lawsuits, centralized before U.S. District Judge Indira Talwani under MDL No. 2768 – in Re: Stryker LFIT V40 Femoral Head Products Liability Litigation.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!